132 data-"https:" "https:" "https:" "https:" "https:" "https:" "University of Exeter" positions at City of Hope
Sort by
Refine Your Search
-
Research Coordinator (ACRC), you'll play a pivotal role in ensuring the integrity of research studies. From data abstraction and completion of case report forms to facilitating sponsor visits and maintaining
-
Journal for Clinicians, Gastroenterology, Cancer Cell, PNAS, JAMA Oncology, JNCI, Cancer Research, Clinical Cancer Research, , Annals of Surgery, etc. For more information on Dr. Goel’s research, please
-
evaluates data and suggests alternative approaches for improvement. · Trains lab staff in specialized procedures, equipment, and theoretical concepts. · Ensures compliance with safety procedures
-
, this patient-facing role involves coordinating First in Human to Phase III and Investigator-Initiated Trials. Responsibilities include patient recruitment, informed consent, trial coordination, data management
-
role involves coordinating First in Human to Phase III and Investigator-Initiated Trials. Responsibilities include patient recruitment, informed consent, trial coordination, data management, and
-
, as needed City of Hope is an equal opportunity employer. To learn more about our comprehensive benefits, click here: Benefits Information City of Hope employees pay is based on the following criteria
-
of coverage analyses, budget estimates, and/or detailed budgets. Negotiates budgets with clinical trial sponsors to ensure optimal cost efficiency. Tracks data and enters, maintains, and reviews financial
-
maintenance of data and source documentation. The CSC collaborates with Investigators in review of subjects’ recruitment and pre-screening efforts for protocol eligibility. The CSC is responsible
-
Atlanta, Chicago and Phoenix. Our dedicated and compassionate employees are driven by a common mission: To deliver the cures of tomorrow to the people who need them today. Collects necessary data to ensure
-
the endogenous immune system. We use this information to design solid-tumor targeted CAR effector cells with improved persistence and potency, as well as the ability to amplify the antitumor immune response. As a